Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004122 · ClinicalTrials.gov registry record · Phase 2
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004122 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute.
The verdict
NCT00004122, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells. Combining these therapies may be an effective treatment for bladder cancer. PURPOSE: Phase II trial to study the effectiveness of BCG plus interferon alfa 2b in treating patients who have bladder cancer.
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL BCG vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004122
The ClinicalTrials.gov registry entry for NCT00004122 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00004122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004122 about?
NCT00004122 is a clinical study titled "BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer". RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells. Combining these therapies may be an effective treatment for bladder cancer. PURPOSE: Phase II trial to stu...
What is the current status of trial NCT00004122?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-07.
What interventions are being tested in trial NCT00004122?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004122?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.